Oxaliplatin Based Chemotherapy and Concomitant Highly Active Antiretroviral Therapy in the Treatment of 24 Patients with Colorectal Cancer and HIV Infection

Author(s): Massimiliano Berretta , Arben Lleshi , Alessandro Cappellani , Alessandra Bearz , Michele Spina , Renato Talamini , Bruno Cacopardo , Giuseppe Nunnari , Vincenzo Montesarchio , Immacolata Izzi , Massimiliano Lanzafame , Guglielmo Nasti , Francesco Basile , Salvatore Berretta , Rossella Fisichella , Clara Schiantarelli , Elisa Garlassi , Annalisa Ridolfo , Lorenza Guella , Umberto Tirelli .

Journal Name: Current HIV Research

Volume 8 , Issue 3 , 2010

Become EABM
Become Reviewer

Abstract:

Background: Although FOLFOX4 is considered the standard chemotherapy regimen for colorectal cancer (CRC), few data are available on its results in human immunodeficiency (HIV)-related CRC. The results were analyzed to evaluate feasibility and activity of FOLFOX4 plus highly active antiretroviral therapy (HAART) in metastatic CRC (mCRC) HIV-seropositive patients. Patients and Methods: From January 2002 to March 2007, 24 patients were selected among the CRC HIV-seropositive patients treated with FOLFOX4 and concomitant HAART within the Italian Cooperative Group on AIDS and Tumors (GICAT). Results: Four median cycles of chemotherapy were administered; the most common severe toxicity was neutropenia (37.5%). An overall response rate of 50% was observed; 4.2% of patients achieved complete response and 45.8% partial response. No opportunistic infections occurred during or immediately after chemotherapy. The medi+ count was 380 (range 220-570) at diagnosis. Conclusions: To our knowledge, this is the largest study describing activity and tolerability of FOLFOX4 and HAART, in this setting. FOLFOX4 plus concomitant HAART resulted feasible and active also in HIV-seropositive patients. Moreover, the concomitant use of HAART did not seem to increase the FOLFOX4 toxicity. This study suggests the good tolerability of the FOLFOX4, making it a reasonable option for combination with HAART.

Keywords: Metastatic Colorectal Cancer, FOLFOX4, HIV-infection, HAART, chemotherapy, treatment

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 8
ISSUE: 3
Year: 2010
Page: [218 - 222]
Pages: 5
DOI: 10.2174/157016210791111061
Price: $58

Article Metrics

PDF: 3